10 Best Immunotherapy Stocks to Buy Now

4. Bristol-Myers Squibb Company (NYSE:BMY)

Number of Hedge Fund Holders: 61

Bristol Myers Squibb Company (NYSE:BMY) is a leading global biopharmaceutical company that ranks highly among the best immunotherapy stocks to buy now.

Bristol Myers Squibb Company (NYSE:BMY) reported strong second-quarter 2024 results, with revenue reaching $12.2 billion, an increase of 9% vs a year ago. The Growth Portfolio, which includes key drugs like Opdivo, Reblozyl, Camzyos, and Opdualag, drove this increase, contributing $5.6 billion.

The company achieved several regulatory milestones, including FDA approval for Breyanzi in additional indications and regulatory filings for subcutaneous nivolumab. Positive clinical trial results for cendakimab, Opdivo, Krazati, and Augtyro further highlight the company’s pipeline potential.

Bristol Myers Squibb Company (NYSE:BMY) also raised its EPS full-year guidance to between $0.60 and $0.90, reflecting a positive outlook. Based on the strong financial performance and pipeline of drugs, the stock has received an average Buy rating.